The Year in Non-ST-Segment Elevation Acute Coronary Syndrome

Journal of the American College of Cardiology

Volumn 52, Issue 13, 2008, Pages 1095-1103

  Giugliano, Robert P ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

coronary; non ST segment; syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIOXIDANT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; ESTROGEN; FIBRINOGEN RECEPTOR ANTAGONIST; FOLIC ACID; FONDAPARINUX; GESTAGEN; GLYCERYL TRINITRATE; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PACLITAXEL; PRASUGREL; PRAVASTATIN; RAPAMYCIN; TICAGRELOR; UNINDEXED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; ECHOCARDIOGRAPHY; HEALTH CARE QUALITY; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; MITRAL VALVE REGURGITATION; MONOTHERAPY; MORTALITY; OPTIMAL DRUG DOSE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; RISK FACTORS;

EID: 51749115755     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.07.005     Document Type: Review

References (79)

1. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50 (2007) e1-e157
2. Bassand J.P., Hamm C.W., Ardissino D., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28 (2007) 1598-1660
3. Rosamond W., Flegal K., Furie K., et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
4. Fox K.A., Steg P.G., Eagle K.A., et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 297 (2007) 1892-1900
5. Ford E.S., Ajani U.A., Croft J.B., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 356 (2007) 2388-2398
6. Hardoon S.L., Whincup P.H., Lennon L.T., Wannamethee S.G., Capewell S., and Morris R.W. How much of the recent decline in the incidence of myocardial infarction in British men can be explained by changes in cardiovascular risk factors?. Evidence from a prospective population-based study. Circulation 117 (2008) 598-604
7. Cesaroni G., Forastiere F., Agabiti N., Valente P., Zuccaro P., and Perucci C.A. Effect of the Italian smoking ban on population rates of acute coronary events. Circulation 117 (2008) 1183-1188
8. Melanson S.E., Tanasijevic M.J., and Jarolim P. Cardiac troponin assays: a view from the clinical chemistry laboratory. Circulation 116 (2007) e501-e504
9. Thygesen K., Alpert J.S., White H.D., et al. Universal definition of myocardial infarction. Circulation 116 (2007) 2634-2653
10. Sanz J., Moreno P.R., and Fuster V. The year in atherothrombosis. J Am Coll Cardiol 51 (2008) 944-955
11. Eikelboom J., Guyatt G., and Hirsh J. Guidelines for anticoagulant use in acute coronary syndromes. Lancet 371 (2008) 1559-1561
12. Kontos M., Jamal S., Tatum J., Ornato J., and Jesse R.L. Predictive power of systolic function and congestive heart failure in patients with patients admitted for chest pain without ST elevation in the troponin era. Am Heart J 156 (2008) 329-335
13. Ariyarajah V., Malinski M., Zieroth S., Harizi R., Morris A., and Spodick D.H. Risk stratification for recurrent heart failure in patients post-myocardial infarction with electrocardiographic and echocardiographic left atrial abnormality. Am J Cardiol 101 (2008) 1373-1378
14. Perez de Isla L., Zamorano J., Quezada M., et al. Functional mitral regurgitation after a first non-ST-segment elevation acute coronary syndrome: contribution to congestive heart failure. Eur Heart J 28 (2007) 2866-2872
15. Bennett K.M., Hernandez A.F., Chen A.Y., et al. Heart failure with preserved left ventricular systolic function among patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 99 (2007) 1351-1356
16. Chang S., Choi S., Choi E., et al. Usefulness of 64-slice multidetector computed tomography as an initial diagnostic approach in patients with acute chest pain. Am Heart J 156 (2008) 375-383
17. Donahoe S.M., Stewart G.C., McCabe C.H., et al. Diabetes and mortality following acute coronary syndromes. JAMA 298 (2007) 765-775
18. Deedwania P., Kosiborod M., Barrett E., et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 117 (2008) 1610-1619
19. Mielniczuk L.M., Pfeffer M.A., Lewis E.F., et al. Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. Am Heart J 155 (2008) 725-731
20. Pickett C.A., Jackson J.L., Hemann B.A., and Atwood J.E. Carotid bruits as a prognostic indicator of cardiovascular death and myocardial infarction: a meta-analysis. Lancet 371 (2008) 1587-1594
21. Mukherjee D., Eagle K.A., Kline-Rogers E., et al. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol 100 (2007) 1-6
22. Ray K.K., Morrow D.A., Sabatine M.S., et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 115 (2007) 3071-3078
23. Morrow D.A., Sabatine M.S., Brennan M.L., et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 29 (2008) 1096-1102
24. Kraaijeveld A.O., de Jager S.C., de Jager W.J., et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 116 (2007) 1931-1941
25. Omland T., Ueland T., Jansson A.M., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 51 (2008) 627-633
26. Tello-Montoliu A., Marin F., Patel J., et al. Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. Eur Heart J 28 (2007) 3006-3011
27. Boos C.J., Soor S.K., Kang D., and Lip G.Y. Relationship between circulating endothelial cells and the predicted risk of cardiovascular events in acute coronary syndromes. Eur Heart J 28 (2007) 1092-1101
28. Altwegg L.A., Neidhart M., Hersberger M., et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 28 (2007) 941-948
29. Morrow D.A., Wang Y., Croce K., et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis In Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J 155 (2008) 49-55
30. Dai D.F., Thajeb P., Tu C.F., et al. Plasma concentration of SCUBE1, a novel platelet protein, is elevated in patients with acute coronary syndrome and ischemic stroke. J Am Coll Cardiol 51 (2008) 2173-2180
31. Iakoubova O.A., Sabatine M.S., Rowland C.M., et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol 51 (2008) 449-455
32. Lanfear D.E., Jones P.G., Marsh S., Cresci S., Spertus J.A., and McLeod H.L. Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome. Am Heart J 154 (2007) 561-566
33. Chen W.Q., Zhang M., Ji X.P., et al. Usefulness of high-frequency vascular ultrasound imaging and serum inflammatory markers to predict plaque rupture in patients with stable and unstable angina pectoris. Am J Cardiol 100 (2007) 1341-1346
34. Zethelius B., Berglund L., Sundstrom J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358 (2008) 2107-2116
35. Gilard M., Arnaud B., Cornily J.C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51 (2008) 256-260
36. Frere C., Cuisset T., Morange P.E., et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 101 (2008) 1088-1093
37. Di Sciascio G. ARMYDA-RELOAD. Presented at: ACC08. March 29, 2008; Chicago, IL.
38. Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51 (2008) 1404-1411
39. Buch A.N., Singh S., Roy P., et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 99 (2007) 1518-1522
40. Ho P.M., Peterson E.D., Wang L., et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 299 (2008) 532-539
41. Wiviott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 (2007) 2923-2932
42. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
43. Wiviott S.D., Braunwald E., McCabe C.H., et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 371 (2008) 1353-1363
44. Antman E.M., Wiviott S.D., Murphy S.A., et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 51 (2008) 2028-2033
45. Storey R.F., Husted S., Harrington R.A., et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50 (2007) 1852-1856
46. Cannon C.P., Husted S., Harrington R.A., et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50 (2007) 1844-1851
47. Moliterno DJ, Jennings L, Becker RC, et al. Results of a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist SCH 530348 in percutaneous coronary intervention. Paper presented at: Annual Meeting of the American College of Cardiology; March 24, 2007; New Orleans, LA.
48. White H.D., Chew D.P., Hoekstra J.W., et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 51 (2008) 1734-1741
49. Gibson C.M., Ten Y., Murphy S.A., et al. Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (a REPLACE-2 analysis). Am J Cardiol 99 (2007) 1687-1690
50. Kastrati A., Neumann F.-J., Mehilli J., et al., ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 359 (2008) 688-696
51. Mehta S.R., Granger C.B., Eikelboom J.W., et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 50 (2007) 1742-1751
52. Fox K.A., Bassand J.P., Mehta S.R., et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med 147 (2007) 304-310
53. Hirsh J., O'Donnell M., and Eikelboom J.W. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 116 (2007) 552-560
54. Chan M.Y., Cohen M.G., Dyke C.K., et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 117 (2008) 2865-2874
55. Gilbert J.C., DeFeo-Fraulini T., Hutabarat R.M., et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116 (2007) 2678-2686
56. Schneider D.J., and Sobel B.E. Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circulation 116 (2007) 305-315
57. Feit F., Voeltz M.D., Attubato M.J., et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 100 (2007) 1364-1369
58. Ndrepepa G., Berger P.B., Mehilli J., et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51 (2008) 690-697
59. Yeh R.W., Wiviott S.D., Giugliano R.P., et al. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. Am J Cardiol 100 (2007) 1734-1738
60. Alexander K.P., Chen A.Y., Wang T.Y., et al. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J 155 (2008) 1047-1053
61. Spencer F.A., Moscucci M., Granger C.B., et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?. Circulation 116 (2007) 2793-2801
62. Melloni C., Alexander K.P., Chen A.Y., et al. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. Am Heart J 156 (2008) 209-215
63. Melloni C., Peterson E.D., Chen A.Y., et al. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 51 (2008) 991-996
64. Brieger D., Van de Werf F., Avezum A., et al. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). Am Heart J 153 (2007) 960-969
65. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49 (2007) 734-739
66. Nguyen M.C., Lim Y.L., Walton A., et al. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. Eur Heart J 28 (2007) 1717-1722
67. Wang T.Y., Robinson L.A., Ou F.S., et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J 155 (2008) 361-368
68. O'Donoghue M., Boden W.E., Braunwald E., Cannon C.P., et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA 300 (2008) 71-80
69. Bauer T., Koeth O., Junger C., et al. Effect of an invasive strategy on in-hospital outcome in elderly patients with non-ST-elevation myocardial infarction. Eur Heart J 28 (2007) 2873-2878
70. Gogo Jr. P.B., Dauerman H.L., Mulgund J., et al. Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative). Am J Cardiol 99 (2007) 1222-1226
71. Tricoci P., Lokhnygina Y., Berdan L.G., et al. Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation 116 (2007) 2669-2677
72. Lee C.H., Tan M., Yan A.T., et al. Use of cardiac catheterization for non-ST-segment elevation acute coronary syndromes according to initial risk: reasons why physicians choose not to refer their patients. Arch Intern Med 168 (2008) 291-296
73. Yan A.T., Yan R.T., Tan M., et al. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J 154 (2007) 1108-1115
74. Devlin G., Gore J.M., Elliott J., et al. Management and 6-month outcomes in elderly and very elderly patients with high-risk non-ST-elevation acute coronary syndromes: The Global Registry of Acute Coronary Events. Eur Heart J 29 (2008) 1275-1282
75. Wong C.K., Newby L.K., Bhapker M.V., et al. Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. Am Heart J 154 (2007) 313-321
76. Roe M.T., Chen A.Y., Delong E., et al. Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals. Am Heart J 156 (2008) 185-192
77. Ho P.M., Luther S.A., Masoudi F.A., et al. Inpatient and follow-up cardiology care and mortality for acute coronary syndrome patients in the Veterans Health Administration. Am Heart J 154 (2007) 489-494
78. Glickman S.W., Boulding W., Staelin R., et al. A framework for quality improvement: an analysis of factors responsible for improvement at hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative. Am Heart J 154 (2007) 1206-1220
79. Choudhry N.K., Patrick A.R., Antman E.M., Avorn J., and Shrank W.H. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation 117 (2008) 1261-1268